ELI LILLY & CO (LLY)
Clinical trial NCT05254743 updates: 1. primary completion date: 2025-06-10 → 2027-10-01 2. enrollment: 662 → 737 participants
Clinical trial NCT05254743 updates: 1. primary completion date: 2025-06-10 → 2027-10-01 2. enrollment: 662 → 737 participants
Clinical trial NCT07448038: start date: 2026-04-30 → 2026-06-15.
Clinical trial NCT07426419: start date: 2026-03-01 → 2026-06-01.
Clinical trial NCT06989840 updates: 1. completion date: 2026-06-01 → 2027-01-01 2. primary completion date: 2026-05-01 → 2027-01-01
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time
Clinical trial NCT05722444 updates: 1. status: UNKNOWN → COMPLETED 2. completion date: 2024-05-31 → 2024-10-17 3. primary completion date: 2024-04-30 → 2024-04-10
Clinical trial NCT07224529 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2026-05-01 → 2026-06-01
Clinical trial NCT07370467 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. completion date: 2026-01-30 → 2026-09-30 3. primary completion date: 2026-01-30 → 2026-09-30
Clinical trial NCT06947408 updates: 1. status: RECRUITING → COMPLETED 2. completion date: 2026-04-23 → 2026-05-11 3. primary completion date: 2026-04-23 → 2026-05-11 4. enrollment: 60 → 44 participants 5. enrollment type: ESTIMATED → ACTUAL
Clinical trial NCT06097728 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. primary completion date: 2027-11-19 → 2028-11-16 3. enrollment: 825 → 861 participants 4. enrollment type: ESTIMATED → ACTUAL